Enhancing anti-gastrointestinal cancer activities of CLDN18.2 CAR-T armored with novel synthetic NKG2D receptors Containing DAP10 and DAP12 signaling domains.
M. Sun, H. Wang, R. Hao, Y. Wang, Y. Li, Y. Zhong, S. Zhang, B. Zhai, Y. Cheng
This paper develops a CAR-T therapy for gastrointestinal cancers by combining CLDN18.2 targeting with synthetic NKG2D receptors containing DAP10 and DAP12 domains, improving efficacy against heterogeneous tumors.
bioRxiv · May 17, 2023 · PreprintImmunology